Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of QL2109 vs Darzalex Faspro in Healthy Males
NCT06371534Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Therapeutic Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QL2109 in multiple myeloma (MM) and light-chain amyloidosis (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity at 112 days and Maximum Observed Concentration at 112 days. Started Apr 2024; status: recruiting.
02
Drugs
QL2109
03
Conditions
multiple myeloma (MM)light-chain amyloidosis
Beyond the preview
Go deeper on NCT06371534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06371534.